The U.S. opioids market consists of prescription and over-the-counter medications used to relieve pain. Opioids work by binding to opioid receptors located in the brain, spinal cord, gastrointestinal tract and other organs in the body. They reduce the intensity of pain signals reaching the brain and affect areas of the brain that control pain response.
The U.S. opioids market is estimated to be valued at USD 7.34 Bn in 2025 and is expected to reach USD 9.60 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.9% from 2025 to 2032.
Key players operating in the U.S. opioids market are Pfizer, Inc., Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals PLC, Mundipharma International, Boehringer Ingelheim International GmbH., Collegium Pharmaceutical, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., Curaleaf, Purdue Pharma L.P., Cresco Labs, Trulieve, Teva Pharmaceutical Industries Ltd., Green Thumb Industries, Trevena, Inc., Par Pharmaceutical, and Emergent BioSolutions Inc.
U.S. Opioids Market Demand has surged due to the rising geriatric population, high incidence of chronic diseases, and injury-related pain. While opioids offer strong pain relief for acute and chronic pain, increasing abuse and misuse have prompted stricter prescribing regulations.
The growing prevalence of clinical conditions like cancer, arthritis and back pain has augmented the demand for effective pain relief solutions. According to estimations, over 50 million adults in the U.S. suffer from chronic pain annually. Opioids are considered the mainstay of treatment for moderate to severe pain not managed by over-the-counter medications. Branded players have also strengthened their market position through new product launches including tamper-resistant opioid formulations and drug delivery systems. Additionally, companies are collaborating with partners to expand geographical presence through exclusive distribution and licensing agreements.
Polypharmacy with the use of multiple therapeutic agents is a key trend gaining traction in the U.S. opioids market. Healthcare providers are increasingly prescribing opioid analgesics in combination with other classes of pain medicines like NSAIDs, antidepressants and anticonvulsants to provide round-the-clock pain relief. While this improves pain management efficacy, it may increase the risk of drug interactions and side effects. Stakeholders are focused on innovative FDA-approved opioids with improved safety profiles and lower abuse potential. Greater emphasis is placed on non-opioid alternatives and complementary therapies for pain.
Porter's Analysis
Threat of new entrants: High capital investments and regulatory barriers create entry challenges.
Bargaining power of buyers: Large buyers like hospitals and pharmacies can negotiate better prices.
Bargaining power of suppliers: Major suppliers like Pfizer and Mundipharma have significant influence over prices.
Threat of new substitutes: Alternatives for pain management reduce market attractiveness.
Competitive rivalry: Intense competition among established players to gain market share through new product launches and expansion of indications.
The U.S. opioids market is highly concentrated in major markets like California, Texas, Florida and New York due to high consumption rates and population densities in these states. California is the leading market contributing over 15% of the total U.S. value sales, followed by Texas, Florida and New York.
The Midwest region is forecast to witness the fastest value growth during the forecast period. This can be attributed to escalating prescription rates and growing acceptance of opioids for chronic pain management. States like Ohio, Michigan, Illinois and Wisconsin will be high potential markets.
Get This Report in Japanese Language -米国のオピオイド市場
Get This Report in Korean Language -미국 오피오이드 시장
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
